Specific Research achievements to date

• The concept of the modular design of prodrugs
  
  
• The genesis of a new approach to cancer therapy, using ionizing radiation to activate prodrugs in hypoxic regions of tumours
  
  
• Development of the first irreversible Tyrosine Kinase inhibitor (Canertinib).
  
  
• Development of the multicellular layer (MCL) technology for measuring the rate of extravascular diffusion of drugs.
  
  
• Development of the amino-CBI class of DNA minor groove alkylators.
  
  
• Development of culture methods for the real-time assessment of the sensitivity of individual patient’s tumours to radiation therapy and to specific drugs, as a tool for individual optimisation of treatment.
  
  
• Demonstration of the cancer-protective effects of specific components of the NZ diet.